|
SELECT PUBLICATIONS
Albain KS et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc ASCO 2004;Abstract 510.
Coombes RC et al. The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen — Updated survival analysis. Presentation. San Antonio Breast Cancer Symposium 2004a;Abstract 3.
Coombes RC et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004b;350(11):1081-92. Abstract
Dowsett M et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol 2005;23(30):7512-7. Abstract
Dowsett M, on behalf of the ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Proc SABCS 2003;Abstract 4.
Ellis MJ et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808-16. Abstract
Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104(2):236-9. Abstract
Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract
Jakesz R et al; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455- 62. Abstract
O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract
Saphner T et al. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14(10):2738-46. Abstract
Thürlimann B et al. Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind Phase III study. Breast 2005a;14(Suppl 1):3;S4. No abstract available
Thürlimann BJ et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presentation. ASCO 2005b;Abstract 511.
Tripathy D et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22(6):1063-70. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
|
